A FOXO4-DRI protocol, in the sense most people mean when they search for one, does not exist. There is no clinical protocol document, no trial design registered with any authority, and no PDF issued by a research group telling a person what to do. FOXO4-DRI has never been administered to a human being in a registered study. What does exist is the experimental design used in the animal work, and that is worth reading properly.
Key takeaways
- No human protocol exists for FOXO4-DRI. Any PDF presenting itself as one is not derived from a clinical source.
- The published mouse work used short, intermittent dosing: three administrations on alternating days, not a continuous course.
- That intermittency is deliberate. Senolytics are designed to clear a cell population and stop, which is a different logic from a drug taken continuously to maintain an effect.
- Experimental protocols specify readouts as much as doses. The senescence markers used are what make a result interpretable.
- Getting from the animal work to a human protocol would require phase 1 safety testing that has not begun.
The vendor we point lifters to
FOXO4-DRI from Ascension Peptides
Independently assayed material, dispatched from the US. The vial drops by half with the code below.
One vial size only, so there is no bulk-tier price break to chase on a single order. Per-mg is quoted at the labelled 10 mg: the two published batch reports measured 11.41 mg and 8.30 mg, so the real figure moves with the batch. Buying 3, 5 or 10 takes 3%, 5% or 10% off. Free shipping starts at $250. The vendor spells the product FOX04 with a zero, including in the link above.
- Batch-specific third-party lab report
- Free delivery above $250
- Same-day dispatch on orders before 2pm CST
Research material, laboratory use only, not for human consumption. FOXO4-DRI is not an approved medicine anywhere and has never been tested in a human trial. Affiliate links: we may earn a commission at no extra cost to you. Pricing verified September 2, 2026.
What a FOXO4-DRI protocol would have to be
It is worth being precise about what the word means, because two very different things are being conflated by search traffic.
A clinical protocol is a formal document. It specifies eligibility criteria, the dose and route, the schedule, the primary and secondary endpoints, the safety monitoring plan, stopping rules, and statistical analysis. It is reviewed by an ethics committee and registered before enrolment. For FOXO4-DRI, no such document exists anywhere, because no human trial has been designed, approved or run.
An experimental protocol is the methods section of a laboratory study. It specifies the model system, the compound, the concentration or dose, the schedule, and how the outcome was measured. Several of these exist for FOXO4-DRI, and they are public.
The material circulating online as a "FOXO4-DRI protocol PDF" is neither. It is generally a compilation authored by someone extrapolating from the animal papers, presented with a confidence the underlying evidence does not support.
How the published experiments were designed
The foundational study is Baar and colleagues, Cell, 2017. Its design is instructive because it did several distinct things rather than one.
The chemotoxicity arm induced senescence in mice using doxorubicin at 10 mg/kg, then administered FOXO4-DRI at 5 mg/kg three times on alternating days, days 1, 3 and 5, intravenously. The readout was whether the peptide neutralised the damage the chemotherapy had caused.
The ageing arms used two different mouse populations: the XpdTTD/TTD strain, which ages rapidly because of a DNA-repair defect, and naturally aged animals. Administration in these cohorts was intraperitoneal. The outcomes measured were fitness, fur density and renal function, which are healthspan endpoints rather than lifespan endpoints.
A third component was in vitro, comparing FOXO4-DRI against other senolytic candidates in cells made senescent by doxorubicin exposure, and testing whether timing relative to the damaging insult mattered.
Later studies followed the same shape in different systems. Work in aged mice examined Leydig cells and testosterone secretion, and spermatogenesis. Other groups applied it to keloid fibroblasts, to bleomycin-induced pulmonary fibrosis in mice, and to human chondrocytes expanded in culture. The chondrocyte study is often miscited as human evidence. It is human cells in a dish, which is a different claim from a human result.
Why the dosing was intermittent
The alternating-day schedule is the design feature most worth understanding, because it reflects a genuine difference in how senolytics are supposed to work.
A conventional drug is usually taken continuously to hold a target occupied or a pathway suppressed. Stop taking it and the effect fades. A senolytic is not trying to hold anything. It is trying to eliminate a cell population that has accumulated, and once those cells are cleared there is nothing further for the compound to act on until more accumulate, which happens over months or years rather than hours.
That produces what is sometimes called hit-and-run dosing: a short exposure sufficient to trigger apoptosis in the target population, then withdrawal. Continuous exposure would add risk without adding benefit, since healthy cells remain in the body throughout and selectivity is never absolute.
This is also why importing the vocabulary of continuous regimens is a mistake. The animal work does not describe a maintenance course, and the framing of an ongoing schedule does not follow from anything published.
What the readouts were, and why they matter
Protocols are often reduced to doses, but in senescence research the measurement is at least as important, because "did it work" is not directly observable.
The standard markers are senescence-associated beta-galactosidase activity, which stains senescent cells; p16 and p21, cell-cycle inhibitors that rise as cells enter senescence; and the secretory profile, the inflammatory cytokines and proteases senescent cells release. The 2017 work also used a p16-driven bioluminescent reporter in mice, allowing senescent-cell burden to be imaged in a living animal over time rather than inferred from tissue at the end.
The mechanism itself has since been characterised further. A 2025 paper in Nature Communications identified the disordered transactivation domain of p53 as the target of both FOXO4 and FOXO4-DRI, which explains at a structural level why the peptide displaces the interaction it was designed to disrupt.
None of these readouts is available to someone outside a laboratory. That is part of why a self-directed protocol would be uninterpretable even in principle: there would be no way to determine whether anything had happened.
What would have to happen next
The gap between where the evidence sits and where a human protocol would begin is a formal one.
It would start with preclinical toxicology across species, establishing a safety margin. Then a phase 1 trial in a small group, whose purpose is not efficacy but tolerability, dose-ranging and pharmacokinetics: how long the peptide persists, how it is cleared, what dose produces unacceptable effects. Only after that does anyone have a defensible starting dose for testing an outcome.
None of this has begun. There is also a reason for caution that any such programme would have to address: senescent cells are not simply refuse. They participate in tumour suppression and wound healing, and removing them carries costs. A 2023 report in Circulation found senescent-cell elimination could promote the development and progression of pulmonary hypertension. A human protocol would need to demonstrate that the balance falls the right way, and that work has not been done.
Frequently asked questions
Is there an official FOXO4-DRI protocol PDF?
No. No clinical protocol exists because no human trial has been designed or registered. Documents circulating under that description are compiled from animal papers by third parties and carry no clinical authority.
What schedule did the animal studies use?
Three administrations on alternating days, days 1, 3 and 5, at 5 mg/kg in mice. Route was intravenous in the chemotoxicity experiments and intraperitoneal in the ageing cohorts. It was a short intermittent burst rather than a continuous course.
Why is senolytic dosing intermittent rather than continuous?
Because the aim is to clear a cell population rather than to maintain a state. Once senescent cells are eliminated there is nothing further to act on until they re-accumulate, which is slow. Continued exposure adds risk without a corresponding benefit.
Has FOXO4-DRI been tested in human cells?
Yes, in culture. A 2021 study applied it to human chondrocytes expanded in vitro and reported selective removal of senescent cells. That is human tissue in a laboratory dish, which is not the same as evidence in a living person, and it is frequently misrepresented as the latter.